Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis
Open Access
- 30 March 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 16 (5), 459-466
- https://doi.org/10.1093/humupd/dmq006
Abstract
Recently, dopamine agonists were proposed as a prophylactic treatment for ovarian hyperstimulation syndrome (OHSS) in women at high risk in IVF/ICSI treatment cycles. We conducted a systematic review and meta-analysis of randomized trials comparing the prophylactic effect of the dopamine agonist, cabergoline, versus no treatment in IVF/ICSI cycles. Primary outcome was OHSS incidence per randomized woman. Secondary outcomes were live birth rate, ongoing pregnancy rate, clinical pregnancy rate and miscarriage rate. Searches (until September 2009) were conducted in MEDLINE, EMBASE, Science Direct, Cochrane Library and databases of abstracts. Four randomized trials entailing 570 women were included. There was evidence of a statistically significant reduction in the incidence of OHSS in the cabergoline group (OR 0.41, 95% CI 0.25–0.66) with an absolute risk reduction of 12% (95% CI 6.1–18.2%), but there was no statistically significant evidence of a reduction in severe OHSS (OR 0.50, 95% CI 0.20–1.26). There was no evidence for a difference in clinical pregnancy rate (OR 1.07, 95% CI 0.70–1.62) and miscarriage rate (OR 0.31, 95% CI 0.03–3.07). Prophylactic treatment with the dopamine agonist, cabergoline, reduces the incidence, but not the severity of OHSS, without compromising pregnancy outcomes.Keywords
This publication has 36 references indexed in Scilit:
- Dopamine agonists and valvular heart diseaseCurrent Opinion in Endocrinology, Diabetes and Obesity, 2009
- GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?Journal of Assisted Reproduction and Genetics, 2008
- The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled studyFertility and Sterility, 2008
- An important new adaption of a specific drug?Fertility and Sterility, 2007
- Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomasFertility and Sterility, 2006
- Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamineGynecological Endocrinology, 2003
- New concepts in the understanding of the ovarian hyperstimulation syndromeCurrent Opinion in Obstetrics and Gynecology, 2003
- Systematic reviews in health care: Assessing the quality of controlled clinical trialsBMJ, 2001
- Pregnancy outcome after treatment with the ergot derivative, cabergolineReproductive Toxicology, 1996
- Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitroJournal of Clinical Endocrinology & Metabolism, 1993